An Observational Study to Investigate the Effectiveness of PK Guided Personalized Recombinant (r)FVIII Treatment in Patients with Hemophilia A
Latest Information Update: 30 Sep 2021
At a glance
- Drugs Rurioctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Sponsors Takeda
- 28 Sep 2021 Status changed from not yet recruiting to recruiting.
- 22 Jul 2021 New trial record